Three Biosimilars on the Market and Hadlima To Come

,

Samsung Bioepis executive Tom Newcomer’s touts the 10-year-old biosimilar company’s achievements as it gets ready to launch its Humira biosimilar, Hadlima.

Fourth of four parts

Tom Newcomer, head of U.S. market access for Samsung Bioepis, talks about his company’s track record during this final segment of his interview with Tony Hagen, a freelance writer and a regular contributor Managed Healthcare Executive

Newcomer talks to Hagen about the three biosimilars that the company has on the market as well as Hadlima (adalimumab-bwwd), the Humira biosimilar that is planning to launch next year.

The three Samsung Bioepis biosimilars already on the market are Byooviz (ranibizumab-nuna), a biosimilar to Lucentis that Biogen is marketing in the U.S.;Renflexis (infliximab-abda), a biosimilar to Remicade; and Ontruzant (trastuzumab-dttb), a biosimilar to Herceptin. Organon, a Jersey City, New Jersey, company is marketing Hadlima, Renflexis and Ontruzant for Samsung Bioepis in the U.S.

Newcomer notes that Byooviz is the first ophthalmic biosimilar; it is FDA-approved as treatment for wet age-related macular degeneration and other eye diseases. He also mentions that Ontruzant as now having five years of data behind it.